A randomized trial of aspirin and sulfinpyrazone in patients with TIA.
In a double-blind multicenter study, 124 patients with transient ischemic attacks were randomly allocated to one of two groups treated with aspirin (ASA) or sulfinpyrazone respectively. Patients were followed up to assess the relative efficacy of the two treatments in the prevention of the outcomes of stroke, myocardial infarction, vascular death, and worsening or no improvement of TIAs. No significant difference was observed between the two treatments at the end of the follow-up period. Statistical analysis revealed a significant interaction of sex, treatment, and occurrence of events. Analysis of the results according to sex showed that male patients treated with ASA had a highly significant benefit (p less than 0.001) with a 53% risk reduction for further events. In female patients, sulfinpyrazone showed a favorable trend which was not statistically significant.
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012306:Risk; D012737:Sex Factors; D013442:Sulfinpyrazone / Q000627:therapeutic use*
D001241:Aspirin; D013442:Sulfinpyrazone